PFIZER busca en Aristotle "the desirable middle between two extremes"

In ancient Greece the philosopher Aristotle thought the golden mean was the desirable middle between two extremes, one of excess and the other of deficiency. In cardiology, apixaban may be the golden mean of anticoagulation, achieving the ideal balance of reduced strokes and deaths without causing any additional bleeding complications.

The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) study compared warfarin to apixaban (5 mg twice daily) in 18,201 patients with AF and at least one additional risk factor for stroke. The overachieving trial demonstrated that apixaban (Eliquis, Pfizer and Bristol-Myers Squibb) was not only noninferior to warfarin in efficacy, it was superior. Further, treatment with apixaban resulted in a statistically significant reduction in mortality, and reduced the risk of major bleeding. The results of ARISTOTLE were presented by Christopher Granger on Sunday morning at the European Society of Cardiology meeting in Paris and published simultaneously in the New England Journal of Medicine.

Ver

Y Galo Sanchez y su Oficina de Evaluación de Medicamentos SES encuentran que:

"...la relevancia´clínica es baja en [Hemorragia mayor], muy baja en [ACV o embolismo sistémico], [Mortalidad total] y [ACV hemorrágico], mientras que no se encuentra difencia significativa en [ACV isquémico o inespecífico].

Sin haber contado Jessica Mega con los NNT, que hubieran puesto mucho mejor en el contexto real la expectativa por apixabán, recomienda que los pacientes que mantienen un buen control del INR (por ejemplo con un tiempo en rango terapéutico del INR igual o mayor a 64%) no sean cambiados desde warfarina a apixabán."

Ver también:

SINTROM sin trono...?

War contra la war_farina. Quién quedará sin_trono